Table 5.
Results of network meta-analysis; Indacaterol 150 μg versus alternatives without covariates
|
Trough FEV1L at 12 weeks |
Trough FEV1L at 6 months |
SGRQ total score at 6 months |
TDI total score at 6 months |
|||||
|---|---|---|---|---|---|---|---|---|
| Difference in CFB (95% CrI) | Prob of IND 150 being better | Difference in CFB (95% CrI) | Prob of IND 150 being better | Difference in CFB (95% CrI) | Prob of IND 150 being better | Difference (95% CrI) | Prob of IND 150 being better | |
| All studies | ||||||||
| SAL/FP 50/500μg | 0.03 (0.00, 0.06) | 99% | 0.01 (−0.04, 0.05) | 61% | −2.16 (−4.96, 0.95) | 92% | −0.69 (−1.38, 0.01) | 3% |
| SAL/FP 50/250 μg | 0.02 (−0.04, 0.08) | 72% | 0.00 (−0.07, 0.07) | 51% | NR | NR | 0.21 (−0.57, 0.99) | 70% |
| FOR/BUD 9/320 μg | 0.09 (0.06, 0.11) | >99% | 0.08 (0.05, 0.12) | >99% | −0.39 (−3.69, 2.92) | 60% | NR | NR |
| FOR/BUD 9/160 μg | 0.11 (0.08, 0.13) | >99% | 0.10 (0.06, 0.14) | >99% | −1.48 (−5.51, 2.61) | 78% | NR | NR |
| All studies excluding 3 Asian studies | ||||||||
| SAL/FP 50/500 μg | 0.04 (0.01, 0.08) | 99% | 0.02 (−0.02, 0.07) | 82% | −3.45 (−6.64, −0.39) | 98% | −0.60 (−1.34, 0.14) | 6% |
| SAL/FP 50/250 μg | 0.03 (−0.04, 0.09) | 80% | 0.01 (−0.06, 0.08) | 66% | NR | NR | 0.30 (−0.51, 1.11) | 76% |
| FOR/BUD 9/320 μg | 0.10 (0.06, 0.13) | >99% | 0.10 (0.05, 0.14) | >99% | −0.86 (−4.20, 2.41) | 71% | NR | NR |
| FOR/BUD 9/160 μg | 0.12 (0.08, 0.15) | >99% | 0.11 (0.07, 0.16) | >99% | −1.92 (−5.88, 2.00) | 85% | NR | NR |
Abbreviations: CFB, change from baseline; CrI, 95% credibility interval; FEV1, forced expiratory volume in 1 second; FOR/BUD, fixed-dose formoterol and budesonide; IND, indacaterol; NR, not reported; Prob, probability; SAL/FP, fixed-dose salmeterol and fluticasone proprionate; SGRQ, St. George’s Respiratory Questionnaire; TDI, Transition Dyspnea Index.